dc.contributor.author | Turkes, F | |
dc.contributor.author | Bryant, A | |
dc.contributor.author | Begum, R | |
dc.contributor.author | Davidson, M | |
dc.contributor.author | Kalaitzaki, E | |
dc.contributor.author | Aresu, M | |
dc.contributor.author | Lazaro-Alcausi, R | |
dc.contributor.author | Bryant, J | |
dc.contributor.author | Rana, I | |
dc.contributor.author | Chua, S | |
dc.contributor.author | Aronson, L | |
dc.contributor.author | Hulkki-Wilson, S | |
dc.contributor.author | Fribbens, C | |
dc.contributor.author | Watkins, D | |
dc.contributor.author | Rao, S | |
dc.contributor.author | Starling, N | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Chong, IY | |
dc.contributor.author | Chau, I | |
dc.date.accessioned | 2022-05-27T09:34:16Z | |
dc.date.available | 2022-05-27T09:34:16Z | |
dc.date.issued | 2022-03-22 | |
dc.identifier.citation | Current oncology (Toronto, Ont.), 2022, 29 (4), pp. 2174 - 2184 | |
dc.identifier.issn | 1198-0052 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5154 | |
dc.identifier.eissn | 1718-7729 | |
dc.identifier.eissn | 1718-7729 | |
dc.identifier.doi | 10.3390/curroncol29040176 | |
dc.identifier.doi | 10.3390/curroncol29040176 | |
dc.description.abstract | Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of ibrutinib in patients with c-MYC and/or HER2 amplified pre-treated advanced OG cancer. c-MYC and HER2 amplification status were determined by FISH. The primary endpoint was overall response rate (ORR). Secondary endpoints were disease control rate (DC) at 8 weeks, safety, progression-free survival (PFS) and overall survival (OS). Eleven patients were enrolled. Eight patients had c-MYC amplified tumours, six were HER2 amplified and three were c-MYC and HER2 co-amplified. Grade ≥ 3 adverse events were fever, neutropenia, and vomiting. Grade ≥ 3 gastrointestinal haemorrhage occurred in three patients and was fatal in two cases. Among seven evaluable patients, three patients (43%) achieved a best response of SD at 8 weeks. No PR or CR was observed. Disease control was achieved for 32 weeks in one patient with a dual c-MYC and HER2 highly co-amplified tumour. The median PFS and OS were 1.5 (95% CI: 0.8-5.1) and 5.1 (95% CI: 0.8-14.5) months, respectively. Ibrutinib had limited clinical efficacy in patients with c-MYC and/or HER2 amplified OG cancer. Unexpected gastrointestinal bleeding was observed in 3 out of 8 treated patients which was considered a new safety finding for ibrutinib in this population. | |
dc.format | Electronic | |
dc.format.extent | 2174 - 2184 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | MDPI | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Humans | |
dc.subject | Esophageal Neoplasms | |
dc.subject | Piperidines | |
dc.subject | Adenine | |
dc.subject | Progression-Free Survival | |
dc.title | Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-03-14 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.3390/curroncol29040176 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2022-03-22 | |
dc.relation.isPartOf | Current oncology (Toronto, Ont.) | |
pubs.issue | 4 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 29 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Gastrointestinal Cancers Clinical Trials | |
icr.researchteam | Medicine (RMH Smith Cunningham) | |
dc.contributor.icrauthor | Chong, Yu-Shing | |